Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences reports developments tied to its immuno-oncology programs for difficult-to-treat cancers. The company’s DNase technology targets neutrophil extracellular traps, or NETs, with a systemic DNase program being advanced as an adjunctive approach for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Recurring updates include preclinical and translational research, conference presentations, collaborations with institutional and development partners, and studies evaluating DNase I with chemotherapy, immunotherapies and CAR T-cell approaches. Company news also covers periodic financial results, cash resources, equity financing, shareholder voting matters and other governance developments.
Xenetic Biosciences (NASDAQ:XBIO) reported on November 13, 2020, progress in advancing its XCART™ platform towards an IND filing and Phase 1 study, including a forthcoming exploratory study in Belarus targeting patients with B-cell lymphomas. The company reported a net loss of approximately $9.7 million for the first nine months of 2020, an improvement from a $11.6 million loss during the same period in 2019. As of September 30, 2020, working capital decreased to $7.2 million. The PolyXen® platform continues to generate royalties, with approximately $0.3 million received in 2020.
Xenetic Biosciences (NASDAQ: XBIO) will host a live video webcast featuring CEO Jeffrey Eisenberg on November 12, 2020, at 8:00 AM EST during the H.C. Wainwright 6th Annual Israel Conference. The event will highlight advancements in the XCART™ personalized CAR T platform, targeting tumor-specific neoantigens for B-cell lymphomas. Following the presentation, management will engage in virtual one-on-one meetings with registered investors. A replay of the webcast will be available two hours post-event and archived for 90 days.
Xenetic Biosciences (NASDAQ: XBIO) will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 12:00 PM EDT, led by CEO Jeffrey Eisenberg. The company focuses on advancing its personalized CAR T platform, XCART™, targeting tumor-specific neoantigens. After the presentation, there will be opportunities for virtual one-on-one investor meetings. A live video webcast will be accessible on the company's website, with a replay available for 90 days.
Xenetic Biosciences (NASDAQ: XBIO) reported its Q2 2020 financial results, highlighting strategic collaborations for its XCART™ CAR T therapy and advancements in PolyXen® technology. The company established partnerships with Scripps Research and Pharmsynthez, aiming to enhance clinical manufacturing and preclinical data generation. Financially, Xenetic recorded a net loss of $2.1 million, with a decrease in working capital to $8.3 million. The company has potential access to a $5 billion annual market for B-cell Non-Hodgkin lymphomas.
Xenetic Biosciences reported its Q2 2020 financial results, achieving key milestones for its differentiated CAR T therapy platform, XCART. The company established collaborations with Scripps Research and Pharmsynthez, enhancing its preclinical development capabilities. For the six months ending June 30, 2020, Xenetic posted a net loss of approximately $2.1 million, down from $2.7 million year-over-year. Working capital decreased to $8.3 million, primarily due to this loss. The company ended the quarter with about $8.1 million in cash, indicating continued investment in its promising oncology pipeline.